Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, tedizolid phosphate (Sivextro®) cannot be endorsed for use within NHS Wales for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adolescents 12 years of age to less than 18 years old. Please refer to the AWMSG position statement on the appraisal of antimicrobial medicines. |
||
|
||
Medicine details |
||
| Medicine name | tedizolid phosphate (Sivextro®) | |
| Formulation | 200 mg film-coated tablet & 200 mg powder for concentrate for solution for infusion | |
| Reference number | 4603 | |
| Indication | Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adolescents 12 years of age to less than 18 years old |
|
| Company | Merck Sharp & Dohme Ltd | |
| BNF chapter | Infections | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 24/06/2021 | |
| Further information AWMSG position statement on the appraisal of antimicrobial medicines |
||